Myriad Genetics says MONITOR-Breast study supports Precise MRD ctDNA test in neoadjuvant monitoring

Myriad Genetics, Inc.

Myriad Genetics, Inc.

MYGN

0.00
  • Myriad Genetics expanded availability of its Precise MRD test to breast, colorectal, and renal cancers.
  • Clinical results were already presented in a new MONITOR-Breast publication in Future Oncology.
  • The study found serial ctDNA monitoring during pre-surgery treatment tracked response in real time and flagged patients at higher residual-disease risk.
  • Management framed the expansion as a step in its precision-oncology strategy, aiming to broaden use across treatment monitoring and long-term surveillance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606230905PRIMZONEFULLFEED9751048) on June 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.